FACTOR V LEIDEN PATIENTS WITH CORONARY ARTERY VEIN GRAFT OCCLUSION

冠状动脉静脉移植物闭塞的 V 因子 LEIDEN 患者

• 批准号: 6122745
• 负责人: DAVID McLeod HERRINGTON
• 金额: $ 3.88万
• 依托单位: WAKE FOREST UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122745
• 关键词: blood vessel transplantation; cardiovascular disorder epidemiology; clinical research; coagulation factor V; gene mutation; human subject; medical complication; transplant rejection; vein occlusion; venous thrombosis

Based on the primary hypothesis that prevalence of the Factor V Leiden mutation will be higher in patients with vein graft occlusions than in those without, this pilot study seeks to estimate the prevalence of the mutation in 100 patients w/ 100 patients without angiographically proven vein graft occlusion. The presence of the mutation is strongly associated w/ deep venous but not arterial thrombotic events. If the association can be established with greater risk of veingraft failure, an argument could be made to avoid vein grafts in pts w/ the mutation.

基于主要假设，莱顿凝血因子V的患病率 静脉移植物闭塞患者中的突变将高于 对于那些没有的人，这项试点研究旨在估计 100例患者中的突变，100例患者中无血管造影证实 静脉移植物闭塞。突变的出现与 w/深静脉血栓形成事件，而非动脉血栓形成事件。 如果协会能够 建立了更大的风险veingraft失败，一个论点可能是 以避免突变患者的静脉移植。